All News

In 2019, you can change your destiny, or you can maintain the status quo. You have a choice: become a drone or remain a dinosaur.

Prucalopride (Motegrity, Shire) is the only serotonin-4 receptor agonist approved for adults with Chronic Idiopathic Constipation.

Prucalopride (Motegrity, Shire) is the only serotonin-4 receptor agonist approved for adults with chronic idiopathic constipation.

Influenza vaccinations among patients with diabetes rose by 20% when they were notified about scheduling their flu shot, according to a new study.

Officials with the FDA have approved prucalopride (Motegrity, Shire) for the treatment of chronic idiopathic constipation.

Specialty pharmacy stakeholders must strike a delicate balance between cost concerns and health outcomes, while keeping the patient at the center.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Patients administered guselkumab achieved an improvement of 90% or more Psoriasis Area Severity Index score than those administered secukinumab.

AMD will affect more than 200 million people globally by 2020 and has become the leading cause of blindness in developed countries.

Despite the completion of CVS Health’s purchase of Aetna in November, the company continues to be challenged over the merger’s potentially harmful effect on consumers and smaller competitors.

CVS' acquisition of Aetna continues to be challenged over the merger’s potentially harmful effect on consumers and smaller competitors.

Two pharmacist groups jointly filed a motion urging the federal judge to block CVS and Aetna from further integration while the potential negative effects are assessed.

Slow-growing gliomas in patients with neurofibromatosis type 1 may be vulnerable to immunotherapy.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Study highlights the importance of testing and early intervention in young patients with hepatitis C virus.

Fentanyl, heroin, hydrocodone, and methamphetamine among the most frequently mentioned drugs connected to overdoses, according to a new report from the CDC.

The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer. 

The FDA has approved trastuzumab-pkrb (Herzuma, Celltrion) as a biosimilar to trastuzumab (Herceptin, Genentech) for the treatment of HER2-overexpressing breast cancer.

Officials with the FDA have approved romiplostim (NPLATE, Amgen) for the treatment of immune thrombocytopenia (ITP) in pediatric patients aged 1 year and older.

Romiplostim (NPLATE, Amgen) approved for the treatment of pediatric patients with immune thrombocytopenia who have had an insufficient response to other therapies.

You have just lost your Job. Now what?!

Updated data from the HAVEN 2 study showed that the majority of children treated with emiciziumab-kxwh (Hemlibra, Genentech) experienced sustained bleed control.

For men living with HIV, stigma associated with the disease may be directly related to cognitive impairment and everyday functioning

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A recent study found further evidence that hepatitis C reinfection rates are greater in drug users despite successful treatment with direct-acting antiviral therapy.

If a pharmacy violates 1 or more of the federal and/or state antifraud laws, then it can have potential criminal liability and potential civil liability, as well as pharmacy license and DEA permit suspension or revocation.